GSK China Executive Departures and Strong H1 2024 Financial Performance

According to the "Pharmaceutical Representative" news on August 14, Ma Zheng, Head of Communications and Government Affairs at GSK China, will leave the company, with the last working day being August 30.

GlaxoSmithKline PLC.No new successor has been announced yet, and this team will be temporarily managed by Leslie Chang, Vice President of GSK, and Head of Communications and Government Affairs for GSK Greater China and Intercontinental Regions.

Recently,GlaxoSmithKline PLC.There were also two personnel changes:

• August 9,GlaxoSmithKline PLC.Peggy Fung, Vice President and Head of GSK's Vaccine Business in China, has officially stepped down.

• On August 1, the Respiratory Business Unit newly established the position of National Sales Director for Nucala (Mepolizumab), which is taken by Hong Xiao; at the same time, the Greater Respiratory Marketing Department was formed, with Cao Xueyan serving as the Head of the Respiratory Marketing Department. Both report directly to Yu Jinyi, the head of the Respiratory Business Unit.

It is worth noting that, at the beginning of this year,GlaxoSmithKline PLC.China has also undergone business restructuring, forming three core business departments: specialty medicines, vaccines, and respiratory.

The latest financial report data shows,GlaxoSmithKline PLC.Revenue in the second quarter of this year was £7.9 billion, a year-on-year increase of 13%. Specifically, vaccine revenue was £2 billion, specialty medicine revenue was £3 billion, and general medicine revenue was £2.9 billion, each achieving growth to varying degrees.

Including the data from the first quarter,GlaxoSmithKline PLC.Total revenue in the first half of the year reached £15.247 billion, a year-on-year increase of 12%.

Based on the strong growth performance,GlaxoSmithKline PLC.Raised the full-year performance forecast from 5%-7% to 7%-9%.